Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, continues its commitment to advancing the cell
analysis market by actively participating in key industry
gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™)
technology, designed for streamlining workflows, expediting
discoveries, and enhancing efficiency, will be prominently featured
at both CYTO 2024 and AAI’s IMMUNOLOGY2024.
The company's distinctive approach to spectral
flow cytometry is renowned for its profound influence on advancing
the understanding of cell biology, immunology, immunotherapy,
oncology and targeted therapeutic methodologies.
IMMUNOLOGY2024May 3,
2024 – May 7, 2024Chicago,
ILBooth #755The American Association of
Immunologists’ (AAI) 107th annual meeting will bring leading
researchers together to explore the latest developments in the
field of immunology. Cytek will be on hand to showcase its complete
cell analysis solutions that enable scientists to advance their
research, gain deeper insights, and fast-track discovery. The
company’s comprehensive, integrated suite of solutions includes the
Cytek portfolio of instruments, reagents, Cytek® Cloud, software
and services.
Also at IMMUNOLOGY2024, Eleanor Kincaid, Ph.D.,
field applications manager, eastern U.S. for Cytek Biosciences,
will host an exhibitor workshop geared toward researchers seeking a
deeper understanding of the complexities of the human immune
system. Titled “High Resolution In-Depth Characterization of the
Human Memory T Cell Compartment Using Full Spectrum Profiling
Technology,” this workshop will take place on Saturday, May 4, from
2:15 p.m. – 3:00 p.m.
CYTO 2024May 4, 2024 –
May 8, 2024Edinburgh,
ScotlandBooths #17 and 98A premier
international conference, CYTO 2024 is where pioneers in flow
cytometry converge to share insights, discoveries, and advancements
in cellular analysis. CYTO serves as a nexus for researchers and
industry leaders to explore the latest technologies, methodologies,
and applications shaping the field. At CYTO, Cytek will showcase
its FSP technology, focusing on its potential to accelerate
scientific discovery. Cytek continues to add product enhancements
to its spectral analyzers, increasing throughput, enabling
walk-away automation, and adding chilling to the automated sample
loader. These enhancements aim to improve lab efficiency and
productivity.
Also at the show, Cytek scientists will conduct
two tutorial sessions. Cytek’s global scientific director, Diana L.
Bonilla Escobar, Ph.D., will lead a session titled, “The Balancing
Act Between Number of Colors and Data Quality: Lessons Learned from
Human Memory T Cells,” on Monday, May 6, from 12:15 p.m. – 1:15
p.m. Additionally, Maria C. Jaimes, M.D., vice president of
scientific commercialization for Cytek, will conduct a session
titled, “Are All Spectral Cytometers Equal? An Analysis from The
Perspective of Multicolor Assay Performance,” on Tuesday, May 7,
from 12:15 p.m. – 1:15 p.m.
"At Cytek, we’re focused on delivering
innovative, powerful solutions that enable scientists to rapidly
and efficiently obtain deep insights and understanding of
biological systems,” said Wenbin Jiang, Ph.D., CEO of Cytek
Biosciences. “Our continued participation in the scientific
community’s most important events underscores our commitment to
providing researchers with the tools they need to drive
groundbreaking discoveries."
For more information, please visit
www.cytekbio.com.
About Cytek Biosciences,
Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell
analysis solutions company advancing the next generation of cell
analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail
preparation system, and reagents, software and services to provide
a comprehensive and integrated suite of solutions for its
customers. Cytek is headquartered in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek
Aurora, Northern Lights, Cytek Orion, Amnis and Guava are
trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s business and product plans and
strategies. These statements are based on management’s current
expectations, forecasts, beliefs, assumptions and information
currently available to management. These statements also deal with
future events and involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as those relating to Cytek’s ability to
manage the growth and complexity of its organization; Cytek’s
ability to manage relationships with key customers and suppliers;
Cytek’s ability to retain key employees; Cytek’s ability to
continue to stay in compliance with its material contractual
obligations, applicable laws and regulations; global economic and
market conditions; competition; and Cytek’s dependence on certain
sole and single source suppliers. You should refer to the section
entitled “Risk Factors” set forth in Cytek’s most recent Quarterly
Report on Form 10-Q filed with the SEC and other filings Cytek
Biosciences makes with the SEC from time to time for a discussion
of important factors that may cause actual results to differ
materially from those expressed or implied by Cytek’s
forward-looking statements. Although Cytek believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Oct 2023 to Oct 2024